ZGNX PDUFA date confirmed. PATH resubmits NDA for migraine. HGSI to be acquired by GSK + MDGN RPRX updates

Jul 17, 2012 No Comments by

Zogenix, Inc. (Nasdaq:ZGNX) announced that the FDA has set a PDUFA date of March 1, 2013 for the Zohydro ER New Drug Application (NDA), for the treatment of moderate to severe chronic pain.

NuPathe Inc. (NASDAQ: PATH) announced that it has resubmitted its NDA for its migraine patch (NP101), with a likely six-month review period by the FDA.

GlaxoSmithKline plc (LSE: GSK) and Human Genome Sciences (NASDAQ: HGSI) announced that they have entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash.

Repros Therapeutics Inc. (NASDAQ: RPRX) announced that the FDA intends to update the full clinical hold to a partial clinical hold of oral Proellex as a treatment for endometriosis, as soon as they have reached agreement on the design of a Phase 2 study protocol. Repros plans to submit the study protocol to the FDA in the next several days.

Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) said it has initiated a Phase 2a clinical trial in Israel of EPODURE Biopumps to treat anemia in patients with end-stage renal disease on dialysis.

 

Daily News

About the author

Currently residing in New Zealand and employed in the education industry, Mr. A. Burden holds a M.Com in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.
No Responses to “ZGNX PDUFA date confirmed. PATH resubmits NDA for migraine. HGSI to be acquired by GSK + MDGN RPRX updates”

Leave a Reply